Bernard Fromenty
Overview
Explore the profile of Bernard Fromenty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3081
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgne-Sanchez A, Fromenty B
Clin Res Hepatol Gastroenterol
. 2025 Jan;
49(3):102529.
PMID: 39798918
Mitochondrial activity is necessary for the maintenance of many liver functions. In particular, mitochondrial fatty acid oxidation (FAO) is required for energy production and lipid homeostasis. This key metabolic pathway...
2.
Fresnais L, Perin O, Riu A, Grall R, Ott A, Fromenty B, et al.
BMC Bioinformatics
. 2024 Jul;
25(1):234.
PMID: 38992584
Background: The growing abundance of in vitro omics data, coupled with the necessity to reduce animal testing in the safety assessment of chemical compounds and even eliminate it in the...
3.
Beausoleil C, Thebault A, Andersson P, Cabaton N, Ermler S, Fromenty B, et al.
Toxicol Appl Pharmacol
. 2024 Jun;
489:116995.
PMID: 38862081
Identification of Endocrine-Disrupting Chemicals (EDCs) in a regulatory context requires a high level of evidence. However, lines of evidence (e.g. human, in vivo, in vitro or in silico) are heterogeneous...
4.
Buron N, Porceddu M, Loyant R, Martel C, Allard J, Fromenty B, et al.
Toxicol Sci
. 2024 Apr;
200(2):369-381.
PMID: 38676573
Drug-induced liver injury (DILI) represents a major issue for pharmaceutical companies, being a potential cause of black-box warnings on marketed pharmaceuticals, or drug withdrawal from the market. Lipid accumulation in...
5.
Petitjean K, Verres Y, Bristeau S, Ribault C, Aninat C, Olivier C, et al.
Chemosphere
. 2023 Nov;
346:140535.
PMID: 37923018
The worldwide and intensive use of phytosanitary compounds results in environmental and food contamination by chemical residues. Human exposure to multiple pesticide residues is a major health issue. Considering that...
6.
Allard J, Bucher S, Ferron P, Launay Y, Fromenty B
Fundam Clin Pharmacol
. 2023 Sep;
38(1):152-167.
PMID: 37665028
Background: The antineoplastic drug busulfan can induce different hepatic lesions including cholestasis and sinusoidal obstruction syndrome. However, hepatic steatosis has never been reported in patients. Objectives: This study aimed to...
7.
Lan A, Guerbette T, Andriamihaja M, Magnin B, Bordet M, Ferron P, et al.
Free Radic Biol Med
. 2023 Jun;
205:224-233.
PMID: 37315703
Mucosal healing has emerged as a therapeutic goal to achieve lasting clinical remission in ulcerative colitis. Intestinal repair in response to inflammation presumably requires higher energy supplies for the restoration...
8.
Begriche K, Penhoat C, Bernabeu-Gentey P, Massart J, Fromenty B
Livers
. 2023 Jan;
3(1):33-53.
PMID: 36713231
The epidemic of obesity, type 2 diabetes and nonalcoholic liver disease (NAFLD) favors drug consumption, which augments the risk of adverse events including liver injury. For more than 30 years,...
9.
Fromenty B, Roden M
J Hepatol
. 2022 Oct;
78(2):415-429.
PMID: 36209983
Fatty liver diseases can result from common metabolic diseases, as well as from xenobiotic exposure and excessive alcohol use, all of which have been shown to exert toxic effects on...
10.
Imran M, Chalmel F, Sergent O, Evrard B, Le Mentec H, Legrand A, et al.
Cell Biol Toxicol
. 2022 Apr;
39(2):371-390.
PMID: 35412187
Non-alcoholic fatty liver disease (NAFLD) is a worldwide epidemic for which environmental contaminants are increasingly recognized as important etiological factors. Among them, the combination of benzo[a]pyrene (B[a]P), a potent environmental...